TREM2阳性巨噬细胞在肝细胞癌经动脉化疗栓塞后抑制CD8阳性T细胞浸润
本研究对5例初治和5例接受经动脉化疗栓塞(TACE)的肝细胞癌(HCC)患者肿瘤样本行单细胞RNA测序,另用22对配对样本以免疫荧光和流式细胞术验证。发现TACE后CD8阳性T细胞减少、肿瘤相关巨噬细胞增多,TREM2在TACE后肿瘤相关巨噬细胞中高表达且与不良预后相关。TREM2阳性肿瘤相关巨噬细胞分泌较少CXCL9但较多半乳糖凝集素-1,后者促进血管内皮细胞PD-L1过表达,阻碍CD8阳性T细胞募集。TREM2缺陷增加CD8阳性T细胞浸润、抑制肿瘤生长并增强抗PD-L1阻断疗效。
要点
- TACE后HCC微环境中CD8阳性T细胞减少、TREM2阳性肿瘤相关巨噬细胞增多。
- TREM2阳性肿瘤相关巨噬细胞分泌半乳糖凝集素-1促进血管内皮PD-L1过表达,阻碍CD8阳性T细胞募集。
- TREM2缺陷增强抗PD-L1阻断疗效,TREM2可能为TACE后HCC免疫治疗新靶点。
核心结论
- TREM2阳性肿瘤相关巨噬细胞在抑制CD8阳性T细胞中起重要作用。
- TREM2缺陷通过增强CD8阳性T细胞抗肿瘤活性提高抗PD-L1阻断的疗效,为TACE后HCC免疫治疗提供新靶点。
研究设计与样本
- 收集5例初治HCC和5例接受TACE治疗患者的肿瘤样本行单细胞RNA测序。
- 另22对配对样本用免疫荧光染色和流式细胞术验证。
- 采用体外共培养实验及两种TREM2基因敲除/野生型小鼠模型(HCC细胞原位注射模型和自发HCC模型)探讨机制。
主要发现
- TACE后微环境中CD8阳性T细胞数量减少、肿瘤相关巨噬细胞数量增加。
- TACE降低CD8_C4簇,该簇高度富集具有耗竭前表型的肿瘤特异性CD8阳性T细胞。
- TACE后肿瘤相关巨噬细胞高表达TREM2,与不良预后相关。
- TREM2阳性肿瘤相关巨噬细胞较TREM2阴性者分泌CXCL9少、半乳糖凝集素-1多。
- 半乳糖凝集素-1促进血管内皮细胞PD-L1过表达,阻碍CD8阳性T细胞募集。
临床怎么用
- 作者认为TREM2可能成为接受TACE治疗的HCC患者的新型免疫治疗靶点。
- 原文未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The immune landscape of hepatocellular carcinoma (HCC) following transarterial chemoembolisation (TACE) remains to be clarified. This study aimed to characterise the immune landscape following TACE and the underlying mechanism of HCC progression. METHODS: Tumour samples from five patients with treatment-naive HCC and five patients who received TACE therapy were collected and subjected to single-cell RNA sequencing. Another 22 paired samples were validated using immunofluorescence staining and flow cytometry. To clarify the underlying mechanisms, in vitro co-culture experiments and two types of TREM2-KO/WT mouse models, namely, an HCC cell orthotopic injection model and a spontaneous HCC model, were used. RESULTS: A reduced number of CD8+ T cells and an increased number of tumour-associated macrophages (TAMs) were observed in the post-TACE microenvironment. TACE therapy reduced the cluster CD8_C4, which was highly enriched with tumour-specific CD8+ T cells of pre-exhausted phenotype. TREM2 was found to be highly expressed in TAMs following TACE, which was associated with a poor prognosis. TREM2+ TAMs secreted less CXCL9 but more galectin-1 than did TREM2- TAMs. Galectin-1 promoted PD-L1 overexpression in vessel endothelial cells, impeding CD8+ T cell recruitment. TREM2 deficiency also increased CD8+ T cell infiltration, which inhibited tumour growth in both in vivo HCC models. More importantly, TREM2 deficiency enhanced the therapeutic effect of anti-PD-L1 blockade. CONCLUSIONS: This study shows that TREM2+ TAMs play an important role in suppressing CD8+ T cells. TREM2 deficiency increased the therapeutic effect of anti-PD-L1 blockade by enhancing antitumour activity of CD8+ T cells. These findings explain the reasons for recurrence and progression after TACE and provide a new target for HCC immunotherapy after TACE. IMPACT AND IMPLICATIONS: Studying the immune landscape in post-TACE HCC is important to uncover the mechanisms of HCC progression. By using scRNA sequencing and functional assays, we discovered that both the number and function of CD8+ T cells are compromised, whereas the number of TREM2+ TAMs is increased in post-TACE HCC, correlating with worse prognosis. Moreover, TREM2 deficiency dramatically increases CD8+ T cell infiltration and augments the therapeutic efficacy of anti-PD-L1 blockade. Mechanistically, TREM2+ TAMs display lower CXCL9 and increased Gal-1 secretion than do TREM2- TAMs, with Gal-1 mediating the overexpression of PD-L1 in vessel endothelial cells. These results suggest that TREM2 could be a novel immunotherapeutic target for patients treated with TACE in HCC. This provides an opportunity to break the plateau of limited therapeutic effect. This study has the value of understanding the tumour microenvironment of post-TACE HCC and thinking a new strategy of immunotherapy in the field of HCC. It is therefore of key impact for physicians, scientists and drug developers in the field of liver cancer and gastrointestinal oncology.
引用
- Tan J, Fan W, Liu T, et al. TREM2+ macrophages suppress CD8+ T-cell infiltration after transarterial chemoembolisation in hepatocellular carcinoma. J Hepatol. 2023. PMID: 36889359. doi:10.1016/j.jhep.2023.02.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。